These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38558635)

  • 41. Torsades de Pointes in atrioventricular septal defect.
    Nijjer S; White S; Gatzoulis MA
    Int J Cardiol; 2009 May; 134(2):e51-2. PubMed ID: 18353464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A canine model of torsades de pointes.
    Leichter D; Danilo P; Boyden P; Rosen TS; Rosen MR
    Pacing Clin Electrophysiol; 1988 Dec; 11(12):2235-45. PubMed ID: 2463611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
    Thomas SH; Behr ER
    Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A practical approach to torsade de pointes.
    Roden DM
    Clin Cardiol; 1997 Mar; 20(3):285-90. PubMed ID: 9068917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Torsades de pointes" and atrioventricular block.
    Moroe K; Saku K; Tashiro N; Hiroki T; Arakawa K
    Clin Cardiol; 1988 Jan; 11(1):9-13. PubMed ID: 3349663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020 Sep; 109(12):944-951. PubMed ID: 32933390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Torsades de Pointes.
    Viskin S
    Curr Treat Options Cardiovasc Med; 1999 Aug; 1(2):187-195. PubMed ID: 11096483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review.
    Brandriss MW; Richardson WS; Barold SS
    Clin Infect Dis; 1994 Jun; 18(6):995-8. PubMed ID: 8086567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Torsades de pointes: arrhythmia, syndrome, or chimera? A perspective in the light of the Lambeth Conventions.
    Curtis MJ
    Cardiovasc Drugs Ther; 1991 Feb; 5(1):191-200. PubMed ID: 2036339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CME ECG 66/Answers: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020; 109(13):1035-1038. PubMed ID: 33050812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
    Eckardt L; Haverkamp W; Mertens H; Johna R; Clague JR; Borggrefe M; Breithardt G
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):425-34. PubMed ID: 9733356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Torsade de pointes, acquired complete heart block and inappropriately long QT in childhood.
    Gladman G; Davis AM; Fogelman R; Hamilton RM; Gow RM
    Can J Cardiol; 1996 Jul; 12(7):683-5. PubMed ID: 8689540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.
    Tisdale JE; Chung MK; Campbell KB; Hammadah M; Joglar JA; Leclerc J; Rajagopalan B;
    Circulation; 2020 Oct; 142(15):e214-e233. PubMed ID: 32929996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Teleological reasoning for QT prolongation caused by severe bradycardia: Correlation between QT interval and brain natriuretic peptide levels during atrioventricular block.
    Barashi R; Milwidsky A; Viskin D; Giladi M; Hochstadt A; Morgan S; Rosso R; Chorin E; Viskin S
    Heart Rhythm; 2024 Jan; 21(1):106-112. PubMed ID: 37757960
    [No Abstract]   [Full Text] [Related]  

  • 58. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block.
    Watanabe O; Okumura T; Takeda H; Nakamura W; Segawa K; Ito H; Yoshimoto N
    Pacing Clin Electrophysiol; 1999 Apr; 22(4 Pt 1):686-8. PubMed ID: 10234727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful Management of Fetal Torsades de Pointes and Long QT Syndrome by a Cardio-Obstetrical Team.
    Putra M; Lee YM; Bucholz E; Ross EL; Galan H; Behrendt N; Micke K; Chow FS; Zaretsky MV; Cuneo BF
    JACC Case Rep; 2023 Dec; 27():102110. PubMed ID: 38094730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.